Ogawa Junji, Nakamura Katsunori, Iizuka Keiko, Sekizuka Masayuki, Yamamoto Koujirou, Horiuchi Ryuya
Department of Pharmacy, Gunma University Hospital, Gunma, Japan.
Yakugaku Zasshi. 2009 Mar;129(3):335-40. doi: 10.1248/yakushi.129.335.
In Japan, the initial dose of 2.5 mg/3 d is recommended in the package insert of the fentanyl patch preparation to substitute for oral morphine in the dose range of 45-135 mg/d (90 mg/d at the midpoint), while a higher dose is recommended in other countries. To validate the recommended dose of this drug in Japan, we investigated how long the initial recommended dose of the fentanyl patch could control the pain of cancer patients after the switch from other opioids. The dose of the fentanyl patch was increased on the 20th day after the switch from prior opioids at a lower dose than the midpoint of the indicated range, while it was increased on the 3rd day after the switch from the higher dose of prior opioids. Regression analysis showed that the efficacy ratio of the fentanyl patch : oral morphine=80 : 1, suggesting that oral morphine of 25-75 mg/d should be substituted for by the fentanyl patch preparation at a dose of 2.5 mg/3 d.
在日本,芬太尼透皮贴剂的包装说明书中推荐初始剂量为2.5毫克/3天,用于替代每日剂量在45 - 135毫克(中点为90毫克/天)范围内的口服吗啡,而其他国家则推荐更高的剂量。为验证该药物在日本的推荐剂量,我们研究了从其他阿片类药物转换后,芬太尼透皮贴剂的初始推荐剂量能控制癌症患者疼痛多长时间。从先前较低剂量阿片类药物转换后,芬太尼透皮贴剂的剂量在第20天增加,该先前剂量低于指示范围的中点;而从较高剂量的先前阿片类药物转换后,芬太尼透皮贴剂的剂量在第3天增加。回归分析表明,芬太尼透皮贴剂与口服吗啡的疗效比为80:1,这表明每日25 - 75毫克的口服吗啡应以2.5毫克/3天的芬太尼透皮贴剂替代。